Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

254.19 +12.73 (+5.27%)
At close: 4:00:01 PM EST
256.30 +2.11 (+0.83%)
After hours: 6:33:55 PM EST
Trade Moderna on Coinbase
MRNA Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Stéphane Bancel M.B.A.
CEO & Director 6.14M 12.41M 1973
Dr. Stephen Hoge M.D.
President 4.26M -- 1976
Mr. James M. Mock
Chief Financial Officer 2.18M -- 1977
Ms. Shannon Thyme Klinger J.D.
Chief Legal Officer & Corporate Secretary 2.18M -- 1971
Mr. Juan Andres
Chief Operating Officer 1.28M 11.47M 1965
Ms. Lavina Talukdar CFA
Senior VP & Head of Investor Relations -- -- 1974
Chris Ridley
VP & Global Head of Communications -- -- --
Ms. Tracey Franklin
Chief People & Digital Technology Officer -- -- 1980
Dr. Charbel Haber M.P.H., Ph.D.
Senior VP & Head of Global Regulatory Science -- -- --
Mr. Patrick Norman Bergstedt
Senior Vice President of Commercial Vaccines -- -- 1962

Moderna, Inc.

325 Binney Street
Cambridge, MA 02142
United States
617 714 6500 https://www.modernatx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4,700

Description

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Moderna, Inc.’s ISS Governance QualityScore as of November 1, 2026 is 10. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 9; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 6, 2026 at 1:30 PM UTC

Moderna, Inc. Earnings Date

Recent Events

November 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 30, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 1, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 31, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 11, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 1, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 16, 2026 at 12:00 AM UTC

ARS: Annual Report to Shareholders

March 5, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 20, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: